Bausch Health Companies Inc. Long-Term Debt, Maturity, Remainder of Fiscal Year
Bausch Health Companies Inc. (BHC) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $29.00 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2026-07-30
- 2026-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $29.00M.
- 2026-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $44.00M.
- 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $314.00M.
- 2025-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $29.00M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $29.00M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $44.00M 10-Q · filed 2026-04-30 |
| 2025-09-30 | $314.00M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $29.00M 10-Q · filed 2025-07-31 |
| 2024-09-30 | $39.00M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $78.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $116.00M 10-Q · filed 2024-05-02 |
| 2023-09-30 | $39.00M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $75.00M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $113.00M 10-Q · filed 2023-05-04 |
| 2022-09-30 | $38.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $75.00M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-02 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-03 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-04 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-03 |
| 2020-06-30 | $1.00M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $4.00M 10-Q · filed 2020-05-07 |
| 2019-09-30 | $100.00M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $4.00M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $182.00M 10-Q · filed 2019-05-06 |
| 2018-09-30 | $125.00M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $114.00M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $2.00M 10-Q · filed 2018-05-08 |
| 2017-09-30 | $923.00M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $811.00M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $260.00M 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |